There are currently 70 active clinical trials seeking participants for Type 1 Diabetes research studies. The states with the highest number of trials for Type 1 Diabetes participants are California, Texas, Florida and Colorado.
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895
Recruiting
The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Sansum Diabetes Research Institute, Goleta, California +147 locations
Conditions: Type 1 Diabetes, Obesity, Overweight
Register for Updates
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06962280
Recruiting
The main purpose of this study is to find out how well and how safely tirzepatide works long-term in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 20 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Kaiser Permanente Bonita Medical Offices, Bonita, California +80 locations
Conditions: Type 1 Diabetes, Obesity, Overweight
Register for Updates
Lipoprotein Kinetics in T1D
NCT05179954
Recruiting
The purpose of this research study is to understand how type 1 diabetes (T1D) increases the risk for cardiovascular diseases (heart attack and stroke). To this end, the investigators will compare apolipoprotein and triglyceride kinetics in people wtih T1D and healthy control participants.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
07/16/2025
Locations: University of Missouri School of Medicine, Columbia, Missouri
Conditions: Type 1 Diabetes
Register for Updates
Family Intervention for Black Teens With Type 1 Diabetes
NCT06275412
Recruiting
The purpose of this study is to conduct a multicenter, randomized effectiveness trial of The 3Ms 2.0 compared to an educational control condition for improving adolescent glycemic control and diabetes-related family relationships and reducing primary caregiver diabetes-related distress among Black adolescents with type 1 diabetes (T1D) and their primary caregivers. The proposed study would develop and test The 3Ms 2.0 adapted intervention when delivered using a mobile health approach (accessed v... Read More
Gender:
ALL
Ages:
Between 10 years and 14 years
Trial Updated:
07/14/2025
Locations: Children's National Hospital, Washington, District of Columbia +3 locations
Conditions: Type 1 Diabetes, Family Relations
Register for Updates
Glu-COACH: a Peer-mentoring Intervention to Reduce Disparities in Continuous Glucose Monitor (CGM) Use
NCT06171412
Recruiting
This is a study to develop and evaluate a peer mentoring intervention for Black and Latinx adolescents with type 1 diabetes to increase the initiation and maintenance of a continuous glucose monitoring (CGM) device. This device is a standard of care to improve diabetes management related to diet, exercise, and insulin. Use of CGM has been shown to improve health outcomes, but is not used by adolescents of color. Peer mentors may help improve usage.
Gender:
ALL
Ages:
Between 13 years and 21 years
Trial Updated:
07/14/2025
Locations: Yale Children's Diabetes Clinic, New Haven, Connecticut
Conditions: Type 1 Diabetes
Register for Updates
ACT1VATE: Addressing Emotional Distress to Improve Outcomes Among Diverse Adults With Type 1 Diabetes
NCT04933851
Recruiting
This research will compare a psychological intervention ("ACT1VATE") versus diabetes self-management education and support (DSME/S; usual care) in improving clinical, behavioral, psychosocial, process, and cost outcomes among adults with poorly controlled type 1 diabetes (T1D) who are experiencing significant diabetes-related emotional distress and poor glycemic control in a real world, healthcare environment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Scripps Whittier Diabetes Institute, San Diego, California
Conditions: Type 1 Diabetes
Register for Updates
Remedy to Diabetes Distress (R2D2): A Scalable Screen to Treat Program for School-age Families
NCT05268250
Recruiting
This R01 is in response to RFA-DK-19-021, Treating Diabetes Distress to Improve Glycemic Outcomes in Type 1 Diabetes. The objective is to test the feasibility and acceptability of a novel, practical, and potentially scalable screen to treat program for diabetes distress in families of school-age children with T1D (called Remedy to Diabetes Distress \[R2D2\]) and to test the initial efficacy of R2D2 to reduce diabetes distress to improve children's glycemic control.
Gender:
ALL
Ages:
Between 8 years and 65 years
Trial Updated:
07/02/2025
Locations: Nemours Children's Health, Jacksonville, Florida +1 locations
Conditions: Type 1 Diabetes
Register for Updates
Description of Patients With Type 1 Diabetes Treated With Teplizumab
NCT06892002
Recruiting
Type 1 diabetes mellitus (T1D) is a chronic autoimmune disease caused by the destruction of pancreatic β cells. T1D pathogenesis progresses through several stages: Stage 1 T1D includes the presence of β cell autoimmunity and thus presence of islet autoantibodies, without the presence of dysglycemia and symptoms. Stage 2 T1D includes the presence of islet autoantibodies and dysglycemia, also with no symptoms. Stage 3 T1D includes presence of islet autoantibodies, overt hyperglycemia, and symptoms... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/01/2025
Locations: Arkansas Children's Hospital Research Institute, Little Rock, Arkansas +11 locations
Conditions: Type 1 Diabetes
Register for Updates
Registry for Stage 2 Type 1 Diabetes
NCT06481904
Recruiting
Stage 2 Type 1 Diabates (T1D) is an early stage of T1D characterized by dysglycemia but not yet leading to clinical symptoms. Progression of the disease to Stage 3 (clinical T1D), leads to overt hyperglycemia requiring eventually exogenous insulin. TZIELD® (teplizumab-mzwv) has been approved to delay onset of stage 3 T1D, by the United States (US) Food and Drug Administration (FDA) for adults and children aged 8 years and older with Stage 2 T1D. The purpose of this study is to collect general... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/30/2025
Locations: University of California San Francisco - Mission Bay- Site Number : 8400005, San Francisco, California +24 locations
Conditions: Type 1 Diabetes
Register for Updates
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
NCT05414409
Recruiting
Obesity prevalence in persons with T1D has increased, which further complicates management and risk for complications. The proposed study is relevant to public health because it helps us understand the role of the gut microbiome in disease pathophysiology in T1D youth with obesity as well as potential mechanisms to modify disease.
Gender:
ALL
Ages:
Between 11 years and 18 years
Trial Updated:
06/18/2025
Locations: Indiana University School of Medicine, Indianapolis, Indiana
Conditions: Type 1 Diabetes, Obesity
Register for Updates
Acetazolamide in Persons With Type 1 Diabetes - Crossover Trial
NCT06981234
Recruiting
The goal of this study is to learn about the effect of the study drug acetazolamide in individuals with Type 1 Diabetes. Specifically, whether acetazolamide provides benefits to the kidneys while minimizing any side effects of the drug. These changes will be measured by laboratory tests that tell us how well the kidneys are functioning.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: UC San Diego Altman Clinical & Translational Research Institute, La Jolla, California
Conditions: Type 1 Diabetes
Register for Updates
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
NCT05822609
Recruiting
The primary objective of this study is to determine the effects of semaglutide on kidney oxygenation and function in type 1 diabetes. The secondary objective is to determine the glycemic effects and safety of semaglutide in type 1 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado +3 locations
Conditions: Diabetic Kidney Disease, Type 1 Diabetes
Register for Updates